Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 8-9, 2012, Pages 943-950

  Clemente, Thayane Rodrigues Leite ^a   Dos Santos, Aline Noronha ^a   Sturaro, José Narciso ^a   Gotardo, Érica Martins Ferreira ^a   De Oliveira, Caroline Candida ^a   Acedo, Simone Coghetto ^a   Caria, Cintia Rabelo E Paiva ^a   Pedrazzoli, José ^a   Ribeiro, Marcelo Lima ^a   Gambero, Alessandra ^a  

^a Universidade Sao Francisco Centro de Ciencias Biologicas e da Saude   (Brazil)

Author keywords

Adipokines; IL 10; INOS; TNBS; TNF

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 10; LEPTIN; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; STRESS ACTIVATED PROTEIN KINASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SIZE; CELL STRAIN U937; CELL VIABILITY; COLITIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; IN VITRO STUDY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 84865766293     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.688213     Document Type: Article

References (34)

1. Shih DQ, Targan SR. Insights into IBD pathogenesis. Curr Gastroenterol Rep 2009;11: 473-80.
2. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006;12: 4807-12.
3. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Müller-Alouf H, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999; 117: 73-81.
4. Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003;27: 987-91.
5. Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005;54: 789-96.
6. Paul G, Schäffler A, Neumeier M, Fürst A, Bataillle F, Buechler C, et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis 2006; 12: 471-7.
7. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007;19: 1070-4.
8. Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A. Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol 2011;4: 9-17.
9. Arijs I, De Hertogh G, Machiels K, Van Steen K, Lemaire K, Schraenen A, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol 2011;106: 748-61.
10. Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, et al. Anti-TNF antibodies target T-cell apoptosis in inflammatory bowel diseases via TNFR2 and intestinal CD14+ macrophages. Gastroenterology 2011;141: 2026-38.
11. Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, et al. Effects of inflixi-mab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm Bowel Dis 2009;15: 1476-84.
12. Gambero A, Maróstica M, Abdalla Saad MJ, Pedrazzoli J Jr. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis 2007;13: 1357-64.
13. Thomaz MA, Acedo SC, de Oliveira CC, Pereira JA, Priolli DG, Saad MJ, et al. Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. Pharmacol Res 2009;60: 341-6.
14. van de Loosdrecht AA, Ossenkoppele GJ, Beelen RH, Broekhoven MG, Dräger AM, Langenhuijsen MM. Apoptosis in tumor necrosis factor-alpha-dependent, monocyte-mediated leukemic cell death: a functional, morphologic, and flow-cytometric analysis. Exp Hematol 1993;21: 1628-39.
15. Martins de Oliveira R, Antunes E, Pedrazzoli J Jr, Gambero A. The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res 2007;56: 105-11.
16. Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol 1995; 268: G622-30.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(DDC (T)) method. Methods 2001;25: 402-8.
18. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106: 685-98.
19. de Oliveira CC, Acedo SC, Pedrazzoli J Jr, Saad MJ, Gambero A. Depot-specific alterations to insulin signaling in mesenteric adipose tissue during intestinal inflammatory response. Int Immunopharmacol 2009;9: 396-402.
20. Acedo SC, Gotardo EM, Lacerda JM, de Oliveira CC, de Oliveira Carvalho P, Gambero A. Perinodal adipose tissue and mesenteric lymph node activation during reactivated TNBS-colitis in rats. Dig Dis Sci 2011;56: 2545-52.
21. Triantafillidis JK, Papalois AE, Parasi A, Anagnostakis E, Burnazos S, Gikas A, et al. Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. World J Gastroenterol 2005;11: 6843-7.
22. Rosillo MA, Sanchez-Hidalgo M, Cárdeno A, de la Lastra CA. Protective effect of ellagic acid, a natural poly-phenolic compound, in a murine model of Crohn's disease. Biochem Pharmacol 2011;82: 737-45.
23. Singh K, Chaturvedi R, Barry DP, Coburn LA, Asim M, Lewis ND, et al. The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. J Biol Chem 2011;286: 3839-50.
24. Schäffler A, Fürst A, Büchler C, Paul G, Rogler G, Schölmerich J, et al. Secretion of RANTES (CCL5) and interleukin-10 from mesenteric adipose tissue and from creeping fat in Crohn's disease: regulation by steroid treatment. J Gastroenterol Hepatol 2006;21: 1412-18.
25. Paul G, Khare V, Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest 2012;42: 95-109.
26. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300: 472-6.
27. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001;98: 502-6.
28. Tiaka EK, Manolakis AC, Kapsoritakis AN, Potamianos SP. The implication of adiponectin and resistin in gastrointestinal diseases. Cytokine Growth Factor Rev 2011;22: 109-19.
29. Cohen G, Ilic D, Raupachova J, Hörl WH. Resistin inhibits essential functions of polymorphonuclear leukocytes. J Immunol 2008;181: 3761-8.
30. Mencarelli A, Distrutti E, Renga B, D'Amore C, Cipriani S, Palladino G, et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 2011;6: e22978.
31. Zulian A, Cancello R, Micheletto G, Gentilini D, Gilardini L, Danelli P, et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut 2012;61: 86-94.
32. De clercq L, Genart C, Boone C, Remacle C. Effects of acute or chronic administration of tumor necrosis factor on rat adipose tissue development. J Anim Sci 1996;74: 2745-51.
33. Isakson P, Hammarstedt A, Gustafson B, Smith U. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes 2009;58: 1550-7.
34. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adi-pocyte differentiation and metabolism-novel insights from genome-wide studies. FEBS Lett 2010;584: 3242-9.